Total Payments
$670,652
2024 Payments
$113,446
Companies
43
Transactions
1,418
Medicare Patients
3,194
Medicare Billing
$659,054
Payment Breakdown by Category
Other$448,877 (66.9%)
Research$88,898 (13.3%)
Travel$67,123 (10.0%)
Food & Beverage$33,623 (5.0%)
Consulting$31,831 (4.7%)
Education$301.03 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $448,877 | 186 | 66.9% |
| Unspecified | $88,898 | 48 | 13.3% |
| Travel and Lodging | $67,123 | 308 | 10.0% |
| Food and Beverage | $33,623 | 858 | 5.0% |
| Consulting Fee | $31,831 | 11 | 4.7% |
| Education | $301.03 | 7 | 0.0% |
Payments by Type
General
$581,754
1,370 transactions
Research
$88,898
48 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $264,307 | 456 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $255,202 | 420 | $0 (2021) |
| Lupin Inc. | $81,742 | 12 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $12,775 | 25 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $8,688 | 41 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $7,764 | 24 | $0 (2020) |
| GlaxoSmithKline, LLC. | $5,719 | 73 | $0 (2024) |
| GENZYME CORPORATION | $5,317 | 69 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $4,355 | 54 | $0 (2023) |
| Actelion Pharmaceuticals US, Inc. | $3,866 | 41 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $113,446 | 180 | AstraZeneca Pharmaceuticals LP ($110,720) |
| 2023 | $67,809 | 124 | AstraZeneca Pharmaceuticals LP ($58,890) |
| 2022 | $66,061 | 139 | AstraZeneca Pharmaceuticals LP ($61,444) |
| 2021 | $39,049 | 119 | AstraZeneca Pharmaceuticals LP ($25,621) |
| 2020 | $24,165 | 97 | Sunovion Pharmaceuticals Inc. ($18,319) |
| 2019 | $90,835 | 239 | Sunovion Pharmaceuticals Inc. ($80,042) |
| 2018 | $183,302 | 296 | Lupin Inc. ($81,742) |
| 2017 | $85,985 | 224 | Sunovion Pharmaceuticals Inc. ($77,693) |
All Payment Transactions
1,418 individual payment records from CMS Open Payments — Page 1 of 57
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | Cash or cash equivalent | $180.78 | General |
| 12/20/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | Cash or cash equivalent | $63.09 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $26.40 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: Immunology | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: Respiratory | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $27.41 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $1,085.07 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $331.03 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $43.50 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $22.13 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: Respiratory | ||||||
| 11/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Immunology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $78,742 | 11 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $3,000 | 1 |
| A Clinical Outcomes Study to compare the effect of Fluticasone Furoate Vilanterol Inhalation Powder 100 25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease COPD and a history of or at increased risk for cardiov | GlaxoSmithKline, LLC. | $2,141 | 7 |
| A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua?100/33 Versus Lantus? in Ethnically/Racially Di | SANOFI US SERVICES INC. | $1,796 | 15 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma | SANOFI US SERVICES INC. | $1,554 | 7 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $1,199 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECT OF PRALUENT ON NEUROCOGNITIVE FUNCTION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR WITH NON-FAMILIAL HYPERCHOLESTEROLEMIA AT HIGH AND VERY HIGH CARDIOVASCULAR RISK | Regeneron Pharmaceuticals, Inc. | $466.35 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 868 | 4,208 | $345,191 | $181,170 |
| 2022 | 15 | 941 | 2,321 | $349,681 | $189,325 |
| 2021 | 16 | 689 | 1,773 | $273,957 | $146,854 |
| 2020 | 12 | 696 | 1,971 | $325,357 | $141,705 |
Total Patients
3,194
Total Services
10,273
Medicare Billing
$659,054
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 1,158 | $236,147 | $119,084 | 50.4% |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | Office | 2023 | 161 | 2,312 | $29,828 | $27,189 | 91.2% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 25 | 234 | $23,275 | $7,731 | 33.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $11,818 | $5,015 | 42.4% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2023 | 13 | 13 | $3,770 | $3,061 | 81.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 39 | 39 | $3,740 | $2,876 | 76.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 48 | 50 | $4,000 | $2,613 | 65.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 49 | 51 | $5,100 | $2,533 | 49.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 31 | $4,216 | $2,284 | 54.2% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 47 | 49 | $7,350 | $1,946 | 26.5% |
| 94728 | Test to measure resistance of the airways and lungs to differing frequencies | Office | 2023 | 49 | 51 | $5,100 | $1,833 | 35.9% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 49 | 51 | $4,437 | $1,760 | 39.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 53 | 53 | $2,385 | $1,741 | 73.0% |
| 94200 | Test to measure largest amount of air breathed in an out | Office | 2023 | 49 | 51 | $2,805 | $684.93 | 24.4% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 14 | 14 | $700.00 | $415.52 | 59.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 13 | 13 | $520.00 | $403.75 | 77.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 218 | 1,236 | $251,632 | $134,489 | 53.4% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2022 | 64 | 64 | $17,720 | $16,088 | 90.8% |
| 96374 | Injection of drug or substance into vein | Office | 2022 | 26 | 248 | $21,093 | $8,921 | 42.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 43 | 43 | $13,373 | $6,320 | 47.3% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 55 | 55 | $4,400 | $3,045 | 69.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 90 | 90 | $3,600 | $2,904 | 80.7% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 53 | 53 | $5,300 | $2,707 | 51.1% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 32 | 32 | $3,278 | $2,248 | 68.6% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 64 | 64 | $2,575 | $2,163 | 84.0% |
About Dr. David Pham, MD
Dr. David Pham, MD is a Pulmonary Disease healthcare provider based in Westminster, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1043401698.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Pham, MD has received a total of $670,652 in payments from pharmaceutical and medical device companies, with $113,446 received in 2024. These payments were reported across 1,418 transactions from 43 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($448,877).
As a Medicare-enrolled provider, Pham has provided services to 3,194 Medicare beneficiaries, totaling 10,273 services with total Medicare billing of $659,054. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Westminster, CA
- Active Since 08/08/2007
- Last Updated 01/25/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1043401698
Products in Payments
- BREZTRI (Drug) $191,018
- LONHALA MAGNAIR (Drug) $155,596
- UTIBRON (Drug) $92,483
- TIOTROPIUM (Drug) $78,742
- AIRSUPRA (Drug) $58,658
- DUPIXENT (Biological) $14,214
- FASENRA (Drug) $7,394
- DUPIXENT DUPILUMAB INJECTION (Biological) $7,094
- ArmonAir Digihaler (Drug) $6,539
- SEEBRI (Drug) $6,515
- AirDuo RespiClick (Drug) $5,372
- Xolair (Biological) $3,310
- ADVAIR (Drug) $3,000
- DUAKLIR (Drug) $2,870
- TRELEGY ELLIPTA (Drug) $2,262
- OPSUMIT MACITENTAN (Drug) $2,026
- SOLIQUA (Drug) $1,796
- Yupelri (Drug) $1,395
- Tresiba (Drug) $1,369
- QBW251 (Drug) $921.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.